Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 4/20 | 0.33 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
| ▸ | CBX7 | O95931 | 1/20 | 0.33 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.33 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506332 | 0.82 | SMN1; SMN2 (0.33) | ALDH1A1SMN1; SMN2ELANE | |
| SCHEMBL5010350 | 0.80 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2CYP19A1PGRSLC9A1 | |
| SCHEMBL13234017 | 0.79 | BMPR1B (0.40) | ALDH1A1SMN1; SMN2CYP19A1ATAD2PGR | |
| SCHEMBL5011601 | 0.79 | ATAD2 (0.47) | ALDH1A1SMN1; SMN2CYP19A1ATAD2PGR | |
| SCHEMBL14609178 | 0.78 | CDYL (0.33) | ALDH1A1SMN1; SMN2PGRELANECDYL | |
| SCHEMBL4512676 | 0.78 | MAPT (0.41) | ALDH1A1SMN1; SMN2KDM4EMAPTMEN1 | |
| SCHEMBL13233812 | 0.78 | SCN9A (0.39) | ALDH1A1CYP19A1ATAD2ELANEKDM4E | |
| SCHEMBL12658804 | 0.73 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2CYP19A1ATAD2CDYL | |
| SCHEMBL4506226 | 0.73 | TDP1 (0.44) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL13233745 | 0.72 | PTGDR2 (0.39) | ALDH1A1ATAD2ELANEGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919920-B1 | PENTACYCLIC KINASE INHIBITORS | GENENTECH INC (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7749994-B2 | Pentacyclic kinase inhibitors | GENENTECH, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749994-B2 | Pentacyclic kinase inhibitors | GENENTECH, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | GEORGES GUY | 2009-11-26 | — | — | US | disclosed |
| CN-101400681-A | Substituted indazole derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2009-04-01 | — | — | CN | disclosed |
| US-7462639-B2 | e.g 3-(7,7-Dimethyl-6-oxo-1,5,6,7-tetrahydro-imidazo[4,5-f]indol-2-yl)-1H-pyrazol-4-yl]-carbamic acid benzyl ester; Aurora A (serotonin/threonine) kinase inhibitors; anticarcinogenic agent; colorectal, breast, lung, prostate, pancreatic, gastric, bladder, ovarian cancer, melanoma, neuroblastoma | HOFFMANN-LA ROCHE INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1885725-B1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | EP | disclosed |
| CN-101160313-A | Aminopyrazole derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | CN | disclosed |
| CN-101160312-A | Tricyclic azole derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | CN | disclosed |
| EP-1885725-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007022102-A2 | PENTACYCLIC KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | HOFFMAN-LAROUCHE, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | HOFFMAN-LAROUCHE, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20060235065-A1 | Aminopyrazole derivatives | HOFFMANN-LA ROCHE INC. | 2006-10-19 | — | — | US | disclosed |
| WO-2006108488-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| US-20060235013-A1 | Tricyclic azole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | CYP3A43, CYP3A5, CYP3A7 | ALDH1A1 88/4885SMN1; SMN2 4281/4885CYP19A1 121/4885 |
| US-20060235013-A1 | Tricyclic azole derivatives | CYP3A5, CYP3A43, CYP11B1 | ALDH1A1 204/4885SMN1; SMN2 3734/4885CYP19A1 30/4885 |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | RAF1, CHEK1, BRAF | ALDH1A1 2759/4885SMN1; SMN2 3254/4885CYP19A1 2336/4885 |
| US-20060235065-A1 | Aminopyrazole derivatives | CYP3A43, CYP3A5, CYP3A4 | ALDH1A1 83/4885SMN1; SMN2 3516/4885CYP19A1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.